Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and Simulation to Evaluate Fexofenadine As a Probe for Hepatobiliary Transport Function

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2009 Jun 5

PMID 19495943

Citations 10

Authors

Brandon Swift

Xianbin Tian

Kim L R Brouwer

Affiliations

Soon will be listed here.

Abstract

Purpose: The suitability of fexofenadine as a probe substrate to assess hepatobiliary transport function in humans was evaluated by pharmacokinetic modeling/simulation and in vitro/in situ studies using chemical modulators.

Methods: Simulations based on a pharmacokinetic model developed to describe fexofenadine disposition in humans were conducted to examine the impact of altered hepatobiliary transport on fexofenadine disposition. The effect of GF120918 on fexofenadine disposition was evaluated in human sandwich-cultured hepatocytes (SCH). Additionally, the effect of GF120918, bosentan, and taurocholate on fexofenadine disposition in perfused livers from TR(-) Wistar rats was examined.

Results: Based on modeling/simulation, fexofenadine systemic exposure was most sensitive to changes in the hepatic uptake rate constant, and did not reflect changes in hepatic exposure due to altered hepatic efflux. GF120918 did not impair fexofenadine biliary excretion in human SCH. GF120918 coadministration significantly decreased Cl'(biliary) to 27.5% of control in perfused rat livers.

Conclusions: Simulations were in agreement with perfused liver data which predicted changes in fexofenadine systemic exposure primarily due to altered hepatic uptake. Fexofenadine is not a suitable probe to assess hepatic efflux function based on systemic concentrations. GF120918-sensitive protein(s) mediate fexofenadine biliary excretion in rat liver, whereas in human hepatocytes multiple efflux proteins are involved in fexofenadine hepatobiliary disposition.

Citing Articles

Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Elmeliegy M, Vourvahis M, Guo C, Wang D Clin Pharmacokinet. 2020; 59(6):699-714.

PMID: 32052379 PMC: 7292822. DOI: 10.1007/s40262-020-00867-1.

Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Kang H, Malinen M, Saran C, Honkakoski P, Brouwer K Drug Metab Dispos. 2019; 47(10):1222-1230.

PMID: 31371422 PMC: 6756293. DOI: 10.1124/dmd.119.087676.

Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes.

Fardel O, Moreau A, Le Vee M, Denizot C, Parmentier Y Eur J Drug Metab Pharmacokinet. 2018; 44(1):13-30.

PMID: 30167999 DOI: 10.1007/s13318-018-0502-x.

BDDCS, the Rule of 5 and drugability.

Benet L, Hosey C, Ursu O, Oprea T Adv Drug Deliv Rev. 2016; 101:89-98.

PMID: 27182629 PMC: 4910824. DOI: 10.1016/j.addr.2016.05.007.

To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Bosgra S, Vlaming M, Vaes W Clin Pharmacokinet. 2015; 55(1):1-15.

PMID: 26242381 DOI: 10.1007/s40262-015-0308-9.

References

LeCluyse E, Bullock P, Parkinson A, Hochman J . Cultured rat hepatocytes. Pharm Biotechnol. 1996; 8:121-59. DOI: 10.1007/978-1-4899-1863-5_9. View

Lemma G, Wang Z, Hamman M, Zaheer N, Gorski J, Hall S . The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006; 79(3):218-30. DOI: 10.1016/j.clpt.2005.11.001. View

Tian X, Zamek-Gliszczynski M, Li J, Bridges A, Nezasa K, Patel N . Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos. 2007; 36(1):61-4. PMC: 2597637. DOI: 10.1124/dmd.107.017319. View

Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y . Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2008; 36(4):663-9. DOI: 10.1124/dmd.107.017814. View

Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H . Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005; 33(10):1477-81. DOI: 10.1124/dmd.105.004622. View

Treiber A, Schneiter R, Delahaye S, Clozel M . Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther. 2003; 308(3):1121-9. DOI: 10.1124/jpet.103.061614. View

Tannergren C, Knutson T, Knutson L, Lennernas H . The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol. 2003; 55(2):182-90. PMC: 1894734. DOI: 10.1046/j.1365-2125.2003.01722.x. View

Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H . Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther. 2003; 74(5):423-36. DOI: 10.1016/S0009-9236(03)00238-8. View

Yasui-Furukori N, Uno T, Sugawara K, Tateishi T . Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005; 77(1):17-23. DOI: 10.1016/j.clpt.2004.08.026. View

10.

Chandra P, Johnson B, Zhang P, Pollack G, Brouwer K . Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab Dispos. 2005; 33(8):1238-43. DOI: 10.1124/dmd.105.003665. View

11.

Byrne J, Strautnieks S, Mieli-Vergani G, Higgins C, Linton K, Thompson R . The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002; 123(5):1649-58. DOI: 10.1053/gast.2002.36591. View

12.

Niemi M, Kivisto K, Hofmann U, Schwab M, Eichelbaum M, Fromm M . Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005; 59(5):602-4. PMC: 1884844. DOI: 10.1111/j.1365-2125.2005.02354.x. View

13.

Cvetkovic M, Leake B, Fromm M, Wilkinson G, Kim R . OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999; 27(8):866-71. View

14.

Glaeser H, Bailey D, Dresser G, Gregor J, Schwarz U, McGrath J . Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007; 81(3):362-70. DOI: 10.1038/sj.clpt.6100056. View

15.

Hamman M, BRUCE M, Hall S . The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001; 69(3):114-21. DOI: 10.1067/mcp.2001.113697. View

16.

Dresser G, Bailey D, Leake B, Schwarz U, Dawson P, Freeman D . Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002; 71(1):11-20. DOI: 10.1067/mcp.2002.121152. View

17.

Tucker G, Houston J, Huang S . Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. Br J Clin Pharmacol. 2001; 52(1):107-17. PMC: 2014497. DOI: 10.1046/j.0306-5251.2001.temp.1441.x. View

18.

Liu X, LeCluyse E, Brouwer K, Gan L, Lemasters J, Stieger B . Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol. 1999; 277(1):G12-21. DOI: 10.1152/ajpgi.1999.277.1.G12. View

19.

Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U . MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002; 53(5):526-34. PMC: 1874364. DOI: 10.1046/j.1365-2125.2002.01591.x. View

20.

Kipp H, Pichetshote N, Arias I . Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem. 2000; 276(10):7218-24. DOI: 10.1074/jbc.M007794200. View